Melanoma is a cancer that arises from pigment-producing melanocytes in the skin. Because of the increasing incidence of melanoma and its resistance to many therapies, insights into melanoma progression are needed. FOXC2, a member of the forkhead box family of transcription factors, has been shown to have oncogenic activity in many epithelial cancer types, and we have recently reported a role for FOXC2 in melanoma progression as well. To gain insight into the role of FOXC2 in melanoma progression, we analyzed publicly available RNA-sequencing data from tumor biopsies of melanoma patients, including a cohort of 479 patients catalogued in The Cancer Genome Atlas as well as additional cohorts from other independent studies. We performed Spearman correlation analyses to identify genes positively and negatively co-expressed with FOXC2, and we performed Impact Pathway Analysis and Gene Ontology Analysis to determine which biological pathways and processes are most impacted by FOXC2-associated genes in melanoma. Our data highlight critical pathways impacted by the expression of FOXC2, and they identify specific genes influenced by this transcription factor that provide mechanistic insight into the oncogenic activity of FOXC2 in melanoma and potentially other cancers.
Citation Format: James B. Wall, Kristian M. Hargadon. Impact pathway analysis of FOXC2-correlated genes in melanoma: A meta-analysis approach to understand the tumor-promoting functions of the FOXC2 transcription factor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2358.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.